Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Jones Lang LaSalle Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.69 (market cap $9.43B), while Jones Lang LaSalle Inc trades at $361.83 (market cap $16.72B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals.
| BIO | JLL | |
|---|---|---|
Market Cap | $9.43B | $16.72B |
Sector | Health | Real Estate |
52-Week High | $356.25 | $373.24 |
52-Week Low | $241.71 | $280.16 |
Enterprise Value | $9.18B | $19.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
JLL trades at $362.81, up 1.53% today, near its 52-week high. The stock exhibits strong technical momentum with a bullish moving average crossover and is supported by consecutive earnings beats in Q4 2025, Q1 2026, and Q2 2026. Revenue growth accelerated to $26.12 billion in 2025, with net income margin improving to 3.64%. Analyst sentiment is positive with a 54.55% buy rating and a consensus price target of $391.50, suggesting further upside potential from current levels.
The outlook for JLL is favorable, driven by robust earnings performance and solid cash flow generation. Key opportunities include continued growth in leasing and capital markets, while risks involve economic sensitivity and competitive pressures in real estate services. The stock's valuation at a P/E of 17.43 and P/S of 0.63 appears reasonable relative to growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
